Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
Premade Virus Particles
Ready-to-Use | High Titer | Versatile Applications
Premade AAV, adenovirus, lentivirus particles, safe, stable, in stock.
Virus-Like Particles (VLPs)
Stable | Scalable | Customizable
Advanced VLPs for vaccine development (Chikungunya, Dengue, SARS-CoV-2), gene therapy (AAV1 & AAV9), and drug screening (SSTR2, CCR5).
Oligonucleotide Products
Precise | High Yield | Tailored Solutions
Accelerate your research with cost-effective LncRNA qPCR Array Technology.
RNA Interference Products
Targeted | Potent | High Specificity
Human Druggable Genome siRNA Library enables efficient drug target screening.
Recombinant Drug Target Proteins
Authentic | Versatile | Accelerated
Providing functional, high-purity recombinant proteins—including membrane proteins and nanodiscs—to overcome bottlenecks in drug screening and target validation.
Clones
Validated | Reliable | Comprehensive Collection
Ready-to-use clones for streamlined research and development.
Kits
Complete | Convenient | High Sensitivity
Chromogenic LAL Endotoxin Assay Kit ensures precise, FDA-compliant endotoxin quantification for biosafety testing.
Enzymes
Purified | Stable | Efficient
Powerful Tn5 Transposase for DNA insertion and random library construction.
Aptamers
Highly Specific | Robust | Versatile
Aptamers for key proteins like ACVR1A, Akt, EGFR, and VEGFR.
Adjuvants
Enhancing | Synergistic | Effective
Enhance immune responses with high-purity, potent CpG ODNs.
Laboratory Equipment
Innovative | Reliable | High-Precision
Effortlessly streamline DNA extraction with CB™ Magnetic-Nanoparticle Systems.
Stable Cell Line Generation
Reliable | Scalable | Customizable
Fast proposals, regular updates, and detailed reports; strict quality control, and contamination-free cells; knockout results in 4-6 weeks.
Target-based Drug Discovery Service
Innovative | Comprehensive | Efficient
Target identification, validation, and screening for drug discovery and therapeutic development.
Custom Viral Service
Versatile | High-Yield | Safe
Unbeatable pricing, fully customizable viral packaging services (covering 30,000+ human genes, 200+ mammals, 50+ protein tags).
Custom Antibody Service
Precise | Flexible | Efficient
End-to-end antibody development support, from target to validation, enabling clients to rapidly obtain application-ready antibodies.
Antibody-Drug Conjugation Service
Integrated | Controlled | Translational
Comprehensive solutions covering design, development, and validation to ensure conjugated drugs with consistent quality and clinical potential.
Protein Degrader Service
Efficient | High-Precision | Advanced Therapeutics
Harness the power of protein degraders for precise protein degradation, expanding druggable targets and enhancing therapeutic effectiveness for cutting-edge drug discovery.
Nucleotides Service
Accurate | Flexible | High-Quality
Custom synthesis of oligonucleotides, primers, and probes for gene editing, PCR, and RNA studies.
Custom RNA Service
Custom RNA ServicePrecise | Flexible | GMP-ReadyCustom
RNA design, synthesis, and manufacturing—covering mRNA, saRNA, circRNA, and RNAi. Fast turnaround, rigorous QC, and seamless transition from research to GMP production.
Custom Libraries Construction Service
Comprehensive | High-throughput | Accurate
Custom cDNA, genomic, and mutagenesis libraries for drug discovery, screening, and functional genomics.
Gene Editing Services
Precise | Efficient | Targeted
Gene editing solutions for gene editing, knockouts, knock-ins, and customized genetic modifications. Integrated multi-platform solutions for one-stop CRISPR sgRNA library synthesis and gene screening services
Microbe Genome Editing Service
Precise | Scalable | Customizable
Enhance microbial productivity with advanced genome editing using Rec-mediated recombination and CRISPR/Cas9 technologies.
Biosafety Testing Service
Reliable | Comprehensive | Regulated
Complete biosafety testing solutions for gene therapy, viral vectors, and biologics development.
Plant Genetic Modification Service
Advanced | Sustainable | Tailored
Genetic modification for crop improvement, biotechnology, and plant-based research solutions.
Plant-based Protein Production Service
Efficient | Scalable | Customizable
Plant-based protein expression systems for biopharmaceuticals, enzyme production, and research.
Aptamers Service
Innovative | Fast | Cost-Effective
Revolutionizing drug delivery and diagnostic development with next-generation high-throughput aptamer selection and synthesis technologies.
CGT Biosafety Testing
Comprehensive | Accurate | Regulatory-compliant
Internationally certified evaluation system for biologics, gene therapies, nucleic acid drugs, and vaccines.
Pandemic Detection Solutions
Rapid | Precise | Scalable
Balancing accuracy, accessibility, affordability, and rapid detection to safeguard public health and strengthen global response to infectious diseases.
cGMP Cell Line Development
Reliable | Scalable | Industry-leading
Stable expression over 15 generations with rapid cell line development in just 3 months.
Supports adherent and suspension cell lines, offering MCB, WCB, and PCB establishment.
GMP mRNA Production
Efficient | Scalable | Precise
Scalable mRNA production from milligrams to grams, with personalized process design for sequence optimization, cap selection, and nucleotide modifications, all in one service.
GMP Plasmid Production
High Quality | Scalable | Regulatory-compliant
Our plasmid production services span Non-GMP, GMP-Like, and GMP-Grade levels, with specialized options for linearized plasmids.
GMP Viral Vector Manufacturing
Scalable | High Yield | Quality-driven
Advanced platforms for AAV, adenovirus, lentivirus, and retrovirus production, with strict adherence to GMP guidelines and robust quality control.
AI-Driven Gene Editing and Therapy
Innovative | Precision | Transformative
AI-powered one-click design for customized CRISPR gene editing strategy development.
AI-Antibody Engineering Fusion
Next-Generation | Targeted | Efficient
AI and ML algorithms accelerate antibody screening and predict new structures, unlocking unprecedented possibilities in antibody engineering.
AI-Driven Enzyme Engineering
Smart | Efficient | Tailored
High-throughput enzyme activity testing with proprietary datasets and deep learning models for standardized and precise enzyme engineering design.
AI-Enhanced Small Molecule Screening
Predictive | Efficient | Insightful
Leverage AI to uncover hidden high-potential small molecules, prioritize leads intelligently, and reduce costly trial-and-error in early drug discovery.
AI-Driven Protein Degrader Drug Development
Innovative | Targeted | Accelerated
Use AI-guided design to optimize protein degraders, addressing design complexity and enhancing efficacy while shortening development timelines.
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
Recent Research Progress
The H2B gene encodes the H2B protein which is a member of the histone family. Related research shows that mono-ubiquitination of H2B (ubH2B) in the histone tail (at Lys-123 in yeast or Lys-120 in humans) is a conserved modification that has been implicated in the regulation of transcription, replication, and DNA repair processes.
Histone H2B ubiquitination plays an important role in transcription regulation, and ubH2B inhibits recruitment of elongation factors. In addition, the splicing factor SART3, which has histone chaperone activity, binds to histones and enhances deubiquitination of H2B by the deubiquitinating enzyme, Usp15. It has recently been reported that ubH2B is enriched at the intron-exon boundaries in yeast, drosophila and humans, suggesting a novel link between ubH2B and co-transcriptional pre-mRNA splicing. It has been shown that H2B K34 ubiquitylation by the mammalian male-specific lethal (MSL) complex (MOF-MSL) is part of the protein networks involved in early steps of transcription elongation.
Histone H2B O-GlcNAcylation is an important posttranslational modification during gene transcription. Recent studies also suggest that histone H2B is O-GlcNAcylated at residue S112 by O-GlcNAc transferase (OGT) in vitro. H2B S112 O-GlcNAcylation fluctuates in response to extracellular glucose through the hexosamine biosynthesis pathway (HBP) and promotes H2B K120 monoubiquitination and transcriptional activation. Here some researchers found that the energy-sensing adenosine-monophosphateactivated protein kinase (AMPK) could suppress histone H2B O-GlcNAcylation.
Some researches proved that phosphorylation of histone H2B at serine 36 (H2BS36) have an effect on fat formation in early period. Some data showed that adipogenic stimuli triggered nuclear translocation of S6K1, leading to H2BS36 phosphorylation and recruitment of enhancer of zeste homolog 2 (EZH2) to histone H3, which mediated trimethylation of H3 at lysine 27 (H3K27). This blocked Wnt gene expression and induced upregulation of proliferator-activated receptor-γ (PPAR γ) and CCAAT/enhancer binding protein-α (C/EBPα), which drived adipogenesis. S6K1, a key downstream effector of the mammalian target of rapamycin (mTOR) signaling pathway, plays a critical role in a number of key catabolic responses, including protein, nucleotide, and lipid synthesis.
Figure 1. Schematic depicting of a role for S6K1 in the transcriptional regulation mediated by H2B phosphorylation and H3 trimethylation. (Sang Ah Yi, et al. 2016).
Several reports show that the Spt-Ada-Gcn5-acetyltransferase (SAGA)-mediated H2B deubiquitination controls the development of neuronal connectivity in the drosophila visual system. Loss of Ataxin-7, a SAGA subunit, reduces H2B ubiquitination and leads to neural and retinal degeneration, impaired movement, and early lethality.
Many studies have reported that reduced ubiquitination of histone H2B (H2Bub1) may create a pro-tumoral microenvironment. And reduced H2Bub1 is associated with colitis and colorectal cancer in humans. H2Bub1, primarily by the ubiquitin ligase (E3) ring finger protein 20 (RNF20), is reduced in many advanced cancers. Notably, colon and colorectal tumors in human ulcerative colitis patient showed downregulation of H2Bub1 and RNF20 in both epithelium and stroma. Tarcic et al. reports that downregulation of H2Bub1 and RNF20 promotes chronic colonic inflammation and inflammation-associated colorectal cancer in mice and humans, partly by augmenting nuclear factor kappa B (NF-kB) activity and attenuating the anti-tumoral T cell response. Downregulation of H2Bub1 and RNF20 favors recruitment of p65-containing NF-kB dimers over repressive p50 homodimers, and decreases the heterochromatin mark histone H3 lysine 9 trimethylation (H3K9me3) on a subset of NF-kB target genes to augment their transcription. What needs to be explained here is that p65 and p50 are subunit of NF-kB transcription factor.
Figure 2. Schematic depicting of downregulation of H2Bub1 and RNF20 promotes chronic colonic inflammation and inflammation-associated colorectal cancer. (Ohad Tarcic, et al. 2016).
Loss of global H2Bub1 detected by immunohistochemical staining has been reported in a number of cancers including breast, colorectal and parathyroid. In the case of parathyroid cancer, a mechanistic explanation for the loss of H2Bub1 is provided by the frequent occurrence of mutations in the tumour suppressor cell division cycle protein 73 homolog (CDC73), leading to the disruption of the RNA polymerase II-associated factor 1 (PAF1) transcriptional complex. Related research shows that basal levels of H2Bub1 were found to be unchanged when comparing normal mammary epithelium with benign breast tumour; however, in malignant and metastatic breast cancer cells, H2Bub1 levels were found to be significantly reduced.
References:
Contact us today for a free consultation with the scientific team and discover how Creative Biogene can be a valuable resource and partner for your organization.
Inquiry
Copyright © Creative Biogene. All rights reserved.